Gastric cancer is the 15th most common type of cancer in the United States. Over 26,000 patients were diagnosed in 2024.1
The NeoGenomics gastric cancer solution supports the care continuum with tests that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options.
Featured gastric cancer solutions
Neo Comprehensive - Solid Tumor
8-10 Days turnaround time
Comprehensive testing for advanced-stage gastric cancer patients
Gastric cancer is challenging to treat, with many patients presenting with advanced disease.2 Biomarker testing has an important role in the diagnosis, classification, and molecular characterization of gastric cancer. It may help oncologists better understand the profile of tumors, and may enable tailored treatment plans for patients with gastric or gastroesophageal junction (GEJ) cancers.
Clinically actionable biomarkers for gastric cancer3-5
MSI, microsatellite instability; TMB, tumor mutation burden.
Add-on testing for therapy selection
PD-L1 28-8 (OPDIVO®) for Gastric/GEJ/EAC
Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time
PD-L1 22C3 FDA (KEYTRUDA®) for Gastric/GEA
Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time
Mismatch Repair (MMR) IHC Panel
Global: 2 Days, Image Analysis (Tech-only): 2 Days, Tech-Only (stain only): 1 Day turnaround time
HER2 Gastric/GEA
Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time
Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma
Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time
Recently approved biomarkers– Claudin18.2
Claudin18 is a new actionable target for patients with advanced or metastatic gastric/GEJ adenocarcinoma who may be eligible for biomarker-driven therapy. NeoGenomics is one of the leading laboratories that offers Claudin18 testing.
Biomarker-informed decision-making reveals opportunities to advance care and provide insight on previously unknown patient populations. Claudin18.2 is a new companion biomarker, making it a useful tool for targeted therapy.
Personalized patient care starts with precision oncology.
70% of gastric/GEJ cancers have Claudin18 at any expression level. 38% of patients have moderate to high expression levels of Claudin18.2 and may benefit from using a targeted biomarker assay to inform treatment decisions that may improve outcomes.6
References
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: stomach cancer. Accessed December 23, 2024. https://seer.cancer.gov/statfacts/html/stomach.html
Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Oncol. 2022;125(7):1104-1109.
Suehnholz SP, Nissan MH, Zhang H, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 2024;14(1):49-65.
Chakravarty D, Gao J, Phillips S, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.
Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO Guideline. J Clin Oncol. 2023;41(7):1470-1491.
Astellas Pharma Inc. Gastric cancer biomarkers: CLDN18.2. Accessed December 23, 2024.
https://www.gastriccancerbiomarkers.com/#cldn18-2-biomarker